Safety standards: An urgent need for Evidence-Based Regulation

"Evidence-based medicine is the conscientious, explicit and judicious use of current best evidence in making decisions about the care of individual patients. ” (Sackett, D. L. et al., 1996). This opinion article describes and analyses some of the consequences of the ever-growing stringency of regulatory standards in the field of drugs and vaccines for human health, with distinct issues in the developed and developing countries. It is argued that the cost and benefit of safety standards, prior and after implementation, are not sufficiently evaluated, nor sufficiently informed by science. We suspect that, as a result, significant amounts of public and private money might be misspent, because assessments of risks/benefits are often questionable, sometimes out of context and inadequate. It is suggested that, just as it happened in medicine 30 years ago, a move towards Evidence-Based Regulation should be promoted. Given the probable and predictable negative impacts on costs and innovation, both in developed and developing countries—particularly in the latter where the needs are huge and the resources highly limited—we contend that such a move is urgently needed.

[1]  R. Chanock,et al.  Reappraisal of the association of intussusception with the licensed live rotavirus vaccine challenges initial conclusions. , 2003, The Journal of infectious diseases.

[2]  J. Stockman,et al.  Safety and Efficacy of a Pentavalent Human-Bovine (WC3) Reassortant Rotavirus Vaccine , 2007 .

[3]  S. Negassi,et al.  Is technology integration the solution to biotechnology's low research and development productivity? , 2006 .

[4]  B. John Randomized Placebo-Controlled Trial of Rhesus-Human Reassortant Rotavirus Vaccine for Prevention of Severe Rotavirus Gastroenteritis , 1998 .

[5]  S. Wolfe,et al.  Timing of new black box warnings and withdrawals for prescription medications. , 2002, JAMA.

[6]  M. Zambon Ethics versus evidence in influenza vaccination , 2004, The Lancet.

[7]  B. Schwartz,et al.  Prevention of rotavirus disease: guidelines for use of rotavirus vaccine. American Academy of Pediatrics. , 1998, Pediatrics.

[8]  R. Kronmal,et al.  Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation. , 2008, JAMA.

[9]  B. Schwartz,et al.  Prevention of Rotavirus Disease: Guidelines for Use of Rotavirus Vaccine , 2007, Pediatrics.

[10]  R. Glass,et al.  The future of rotavirus vaccines: a major setback leads to new opportunities , 2004, The Lancet.

[11]  B. Schwartz,et al.  Intussusception among infants given an oral rotavirus vaccine. , 2001, The New England journal of medicine.

[12]  Catherine D DeAngelis,et al.  Impugning the integrity of medical science: the adverse effects of industry influence. , 2008, JAMA.

[13]  C. Weijer The future of research into rotavirus vaccine , 2000, BMJ : British Medical Journal.

[14]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[15]  M Elizabeth Halloran,et al.  Strategy for distribution of influenza vaccine to high-risk groups and children. , 2005, American journal of epidemiology.

[16]  J. Collier Regulating Medicines in Europe: Competition, Expertise and Public Health , 2001, BMJ : British Medical Journal.

[17]  R. Holman,et al.  Cost-effectiveness analysis of a rotavirus immunization program for the United States. , 1995, JAMA.

[18]  X. Pang,et al.  Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis , 1997, The Lancet.

[19]  M. Martuzzi The precautionary principle: in action for public health , 2007, Occupational and Environmental Medicine.

[20]  R. Glass,et al.  Rotavirus vaccine for the prevention of rotavirus gastroenteritis among children : recommendations of the Advisory Committee on Immunization Practices (ACIP) , 1999 .

[21]  Keiji Fukuda,et al.  Mortality associated with influenza and respiratory syncytial virus in the United States. , 2003, JAMA.

[22]  J. Heyse,et al.  Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. , 2006, The New England journal of medicine.

[23]  S. Reef,et al.  Measles, Mumps, and Rubella - Vaccine Use and Strategies for Elimination of Measles, Rubella, and Congenital Rubella Syndrome and Control of Mumps: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Vol. 47/No. RR-8. , 1998 .

[24]  D. Kerr,et al.  Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. , 2007, The New England journal of medicine.

[25]  James L. Gilbert,et al.  Rebuilding Big Pharma ’ s Business Model , 2022 .

[26]  D. Kriebel,et al.  Reenergizing public health through precaution. , 2001, American journal of public health.

[27]  Harlan M Krumholz,et al.  Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. , 2008, JAMA.

[28]  C. Mathers,et al.  Projections of Global Mortality and Burden of Disease from 2002 to 2030 , 2006, PLoS medicine.

[29]  Meredith Wadman,et al.  Regulator under siege , 2007, Nature.

[30]  C. Victora,et al.  Applying an equity lens to child health and mortality: more of the same is not enough , 2003, The Lancet.

[31]  L. Melton Lifesaving vaccine caught in an ethical minefield , 2000, The Lancet.

[32]  B. Strom,et al.  How the US drug safety system should be changed. , 2006, JAMA.

[33]  A. Elixhauser,et al.  Effect of rotavirus vaccination programme on trends in admission of infants to hospital for intussusception , 2001, The Lancet.

[34]  Robert T. Chen,et al.  Population-based study of rotavirus vaccination and intussusception , 2001, The Pediatric infectious disease journal.

[35]  P. Heuveline,et al.  The burden of disease among the global poor , 1999, The Lancet.

[36]  Withdrawal of rotavirus vaccine recommendation. , 1999, MMWR. Morbidity and mortality weekly report.

[37]  D. Sackett,et al.  Evidence based medicine: what it is and what it isn't , 1996, BMJ.

[38]  B. Goldstein,et al.  The precautionary principle also applies to public health actions. , 2001, American journal of public health.